Abstract

BackgroundEndophytic actinomycetes are well known for their diverse bioactive entities and considered as an important source for drug development research. ResultsWe isolated and identified four potential endophytic Streptomyces species, i.e., Streptomyces misionensis MI22, Streptomyces roietensis MI24, Streptomyces glaucescens MI29, and Streptomyces sp. MI04 inhabiting Madhuca insignis by its characteristic morphological features and 16S rRNA gene sequence analysis. S. misionensis MI22 exhibits a broad spectrum of anti-microbial activity against methicillin-resistant Staphylococcus aureus (25.00 ± 1.00 mm) followed by Bacillus subtilis (23.66 ± 0.57 mm), Escherichia coli (22.00 ± 0.00 mm), and Candida albicans (18.00 ± 0.00 mm). Minimum inhibitory concentrations of the ethyl acetate fraction of S. misionensis MI22 against test pathogens were ranged from 25 to 100 μg/mL. Indeed, strain MI22 also exhibited significant anti-proliferative activity against HeLa cell line with IC50 value 98 μg/mL and showed no cytotoxicity effect to the normal human embryonic kidney cell line in the MTT assay. The anti-microbial metabolites from strain MI22 were detected at Rf 0.55 as depicted by the inhibition zone on the intensive band in TLC-bioautography assay. ConclusionThe study indicates that, anti-microbial metabolites of these endophytic Streptomyces species, especially S. misionensis MI22 as a prolific source to discover novel bioactive metabolites to combat multidrug-resistant pathogens.

Highlights

  • Endophytic actinomycetes are well known for their diverse bioactive entities and considered as an important source for drug development research

  • We describe the taxonomic position of isolates together with phylogenetic and morphological characteristics

  • This research indicates that targeting under-explored medicinal plants to explore hidden endophytic actinomycetes are a prolific source to discover new bioactive agents

Read more

Summary

Introduction

Endophytic actinomycetes are well known for their diverse bioactive entities and considered as an important source for drug development research. Natural products or secondary metabolites originate from plants, bacteria, marine, and fungal sources are the most successful source of potent lead natural drugs [3]. They serve as a continuing potent source of novel bioactive agents, retaining an immense impact on modern medicine [4]. Antibiotic drugs like erythromycin, methicillin, and penicillin are used in a great extent to treat various diseases, but currently turning to be less potent as a result of many microbes become resistant to certain antibiotics [5]. The right solution to cover the problem of drug-resistant pathogens is to explore and discover new biomolecules

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call